| Volume: | 9,027,242 |
|---|---|
| Day's Low: | $34.16 |
| 52-wk Low: | $27.21 |
| Previous Close: | $34.43 |
| Dividend: | $0.49 |
| Market Cap: | 39,641,300 |
| Avg Volume: | 6,823,900 |
|---|---|
| Day's High: | $34.53 |
| 52-wk High: | $40.78 |
| Open Price: | $34.39 |
| Yield: | 5.68% |
| P/E (Forward): | 7.84 |
| 1:06 PM | 11/5/2009 | Amgen's Vectibix Misses Survival Goal,But Sales Could Benefit |
| 10:24 AM | 11/3/2009 | Eli Lily & Co To Boost Chorus Unit - Executive |
| 4:48 PM | 11/2/2009 | UPDATE:FDA Approves New Byetta Label Amid Renal-Failure Reports |
| 8:19 AM | 10/29/2009 | UPDATE: Roche's New Diabetes Drug Works Better Than Byetta |
| 4:48 AM | 10/29/2009 | Roche: New Diabetes Drug Works Better Than Byetta - Study |
| 11:39 AM | 10/23/2009 | EU Body Recommends Generic Version Of Pfizer's Viagra |
| 9:21 AM | 10/23/2009 | EU Panel: Positive Opinion On Sildenafil Ratiopharm |
| 11/4/2009 | Still Waiting for Details on Merck's 16,000 Job Cuts |
| 11/3/2009 | Pharma's Hiring! (In China) |
| 11/3/2009 | Recapping 40,000 Job Cuts in Big Pharma |
| 11/3/2009 | A Tutorial in Defensive Investing |
| 10/30/2009 | Drug stocks slip; Ipsen gains for second day |
| 10/30/2009 | Yet Another Qui Tam Grand Slam |
| 10/28/2009 | Where GSK Is Cutting Sales Reps, and Where It's Adding Them |
| Most Recent Quarter ($) | Same Quarter Last Year ($) | % Change | |
| EPS, Pro Forma | 1.20 | 1.04 | 15.38 |
| EPS, GAAP | 0.86 | -0.43 | NA |
| Consensus Estimate | 1.02 | 1.01 | 0.99 |
| Trailing 12 Months | Year-Earlier Period | % Change | |
| EPS, Pro Forma | 4.59 | 4.02 | 14.18 |
| EPS, GAAP | -0.19 | 2.20 | NA |
| Consensus Estimate | 4.08 | NA | NA |
| LLY | Industry Average | |
| P/E (TTM) | -181.58 | 18.40 |
| P/E (Forward) | 7.84 | -4.30 |
| PEG Ratio | 2.24 | -0.28 |
| Price/Sales | 1.79 | 2.94 |
| Beta | 0.79 | 0.83 |